Clinical trials: Gerd
Erosive Esophagitis, Heartburn
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily or vonoprazan 20 mg administered twice daily for 4…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06391177
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Phathom Pharmaceuticals, Inc.
Gastroesophageal Reflux Disease (GERD)
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD)…
- Trial name
- NCT03561883
- Testing
- IW-3718, Standard-dose PPIs QD
- Where
- 101 sites in United States, Canada
- Volunteers
- 609 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroesophageal Reflux
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.
- Trial name
- NCT01135368
- Testing
- Lansoprazole
- Volunteers
- 506 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive…
- Trial name
- NCT00787891
- Testing
- rabeprazole
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Laryngopharyngeal Reflux
Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration…
- Trial name
- NCT01857713
- Testing
- Reza Band UES Assist Device
- Where
- 5 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Somna Therapeutics, L.L.C.
Gastroesophageal Reflux Disease
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a…
- Trial name
- NEON (NCT00734097)
- Testing
- Esomeprazole 40 mg, Physical Exam, Quality of Life Questionnaires
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent…
- Trial name
- NCT01472939
- Testing
- SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI
- Where
- 88 sites in United States, Czechia and 4 more
- Volunteers
- 480 people
- Sponsor
- Shire
Gastroesophageal Reflux Disease
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
The purpose of this study is to assess the efficacy and safety of rabeprazole 10mg once and twice daily in maintenance therapy for PPI resistant gastroesophageal reflux disease patients.
- Trial name
- NCT02135107
- Testing
- Rabeprazole
- Where
- 61 sites in Japan
- Volunteers
- 517 people
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux Disease (GERD)
Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)
The study is designed to test the safety and efficacy of the Medigus SRS endoscopic stapling system for the treatment of GERD. The system allows the operator to staple the stomach to the esophagus,in order to restore the…
- Trial name
- NCT00734747
- Testing
- Medigus SRS endoscopic stapling system
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 72 people
- Sponsor
- Aviel Roy-Shapira, M.D.
Gastroesophageal Reflux Disease (GERD)
Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to compare the efficacy of rabeprazole extended release 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive…
- Trial name
- NCT00839306
- Testing
- Rabeprazole ER, Ranitidine
- Where
- 4 sites in United States
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn…
- Trial name
- NCT00251758
- Testing
- Dexlansoprazole MR
- Where
- 99 sites in United States
- Volunteers
- 908 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease, Erosive Esophagitis
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.
- Conditions
- Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
- Trial name
- NCT02096458
- Testing
- Dexlansoprazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Takeda
Gastroesophageal Reflux
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
- Trial name
- NCT01045096
- Testing
- Dexlansoprazole
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease
Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal…
- Trial name
- NCT01872897
- Testing
- Sodium Alginate Double Action Chewable Tablets
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Gastroesophageal Reflux Disease
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease.
- Trial name
- NCT00255190
- Testing
- Dexlansoprazole MR
- Where
- 181 sites in United States
- Volunteers
- 591 people
- Sponsor
- Takeda
GERD
Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects
This is a Phase I, single-center, open label parallel-group, randomized study designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD, by continuous intragastric pH measurment), safety and tolerability of single and…
- Trial name
- NCT05742984
- Testing
- linaprazan glurate 25 mg QD, linaprazan glurate 50 mg QD, linaprazan glurate 75 mg QD
- Where
- Slovenia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Cinclus Pharma Holding AB
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda
Reflux
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
- Trial name
- NCT01154634
- Testing
- AZD2516, 5 mg, AZD2516, 16 mg, AZD2516, 40 mg
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Tricuspid Regurgitation
Edwards CLASP TR EFS
Early feasibility study to assess the safety and performance of the Edwards PASCAL Transcatheter Valve Repair System in tricuspid regurgitation
- Trial name
- CLASP TR EFS (NCT03745313)
- Testing
- Edwards PASCAL Transcatheter Valve Repair System
- Where
- 15 sites in United States
- Volunteers
- 65 people
- Sponsor
- Edwards Lifesciences
Gastroesophageal Reflux Disease
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
The purpose of this study is to characterize the pharmacokinetics (PK) and safety of intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid suppression therapy.
- Trial name
- NCT02401035
- Testing
- IV pantoprazole
- Where
- 19 sites in United States, Argentina and 7 more
- Volunteers
- 19 people
- Sponsor
- Pfizer